Salle de presse | Merck Canada

MERCK DANS L'ACTUALITÉ

DERNIÈRES NOUVELLES

Le 15 octobre 2020
Santé Canada approuve KEYTRUDA^® (pembrolizumab) comme traitement de première intention pour les patients atteints d’un carcinome épidermoïde de la tête et du cou métastatique ou non résécable récurrent

Le 24 septembre 2020
L’implant contraceptif pour insertion sous-cutanée dans le bras NEXPLANON^® est maintenant offert au Canada

Le 15 septembre 2020
BRENZYS®️ (injection d’étanercept) maintenant indiqué pour le traitement du psoriasis en plaques, du rhumatisme psoriasique et de l’arthrite juvénile idiopathique

Le 27 août 2020
GARDASIL^®9, le vaccin contre le VPH de Merck, maintenant indiqué chez les garçons et les hommes de 9 à 45 ans

Le 27 mai 2020
Merck annonce trois efforts scientifiques importants dans la lutte contre la COVID-19

Le 4 mai 2020
Merck Canada annonce un soutien accru pour les collectivités, les patients et les travailleurs de la santé canadiens touchés par la COVID-19

Le 3 avril 2020
Merck Canada est fière de se joindre à Médicaments novateurs Canada et à d'autres sociétés pharmaceutiques pour aider les travailleurs de la santé de première ligne à lutter contre la COVID-19

Le 13 mar 2020
Déclaration de Merck Canada concernant COVID-19

Le 4 mar 2020
Santé Canada approuve KEYTRUDA^®️ (pembrolizumab) comme traitement de première intention pour les patients atteints d’un adénocarcinome rénal (AR) à un stade avancé

Le 18 nov 2019
L’Ontario et le Québec permettent le remboursement des traitements anti-VIH PIFELTRO^®️ (doravirine) et DELSTRIGO^®️ (doravirine, lamivudine et fumarate de ténofovir disoproxil)

CENTRE DE PRESSE

Pour les demandes de renseignements de la part de représentants des médias, veuillez composer le 1-833-90MERCK (1-833-906-3725).

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.